tiprankstipranks
Trending News
More News >

Disc Medicine resumed with a Strong Buy at Raymond James

Raymond James resumed coverage of Disc Medicine (IRON) with a Strong Buy rating and $89 price target as part of a broader research note on selection Biotech names. Risk/reward skews favorably across the sector, though while companies with high PoS – probability of success – lead assets allow for higher conviction, highly attractive skews on less de-risked assets may deliver the most outsized returns, the analyst tells investors in a research note. For the company, the firm believes that as the first disease-modifying agent to treat EPP/XLP, Disc Medicine can deliver on $1B ore more in bitopertin sales with about 30%-35% penetration of the initial 6K focus EPP population, Raymond James added.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1